Organogenesis vs Vericel
ORGO and VCEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ORGO and VCEL compare
Vericel is the larger company, worth 23 times as much as Organogenesis ($3.0B against $135M).
Vericel grew revenue faster over the last twelve months (25.3% versus −24.3% for Organogenesis).
Vericel keeps more of each dollar of sales as profit, with a net margin of 10.3% compared with −38.4% at Organogenesis.
Vericel scores higher on the StockData Score (16 against 8 for Organogenesis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ORGO | VCEL |
|---|---|---|
| Size and price | ||
| Market cap | $135M | $3.0B |
| Share price | $1.05 | $59.45 |
| Change, 1 year | −83.9% | 52.5% |
| Change, 5 years | −89.4% | 34.1% |
| Beta (5Y) | 1.18 | 1.04 |
| Employees | 854 | 398 |
| StockData Score | ||
| Total score | 8 | 16 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 5 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 101× |
| P/S | 0.4× (better) | 9.4× |
| P/B | 1.1× (better) | 7.9× |
| EV/EBITDA | – | 70.8× |
| P/FCF | – | 52.6× |
| FCF yield | −0.05% | 1.9% (better) |
| Fair value | – | $16.78 |
| Margin of safety | – | −254% |
| Growth | ||
| Revenue growth (TTM) | −24.3% | 25.3% (better) |
| Revenue growth, 5Y average | 10.8% | 17.3% (better) |
| Net income growth (TTM) | −13568% | 155% (better) |
| EPS growth (TTM) | – | 211% |
| EPS growth, 5Y average | 0.00% | 39.8% (better) |
| Profitability | ||
| Gross margin | – | 74.5% |
| Operating margin | −24.5% | 8.3% (better) |
| Net margin | −38.4% | 10.3% (better) |
| FCF margin | −0.02% | 17.9% (better) |
| Return on equity | −72.2% | 9.4% (better) |
| Return on invested capital | −47.0% | 10.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | 42.0× |
| Current ratio | 3.32 | 5.13 (better) |
| Altman Z-score | 0.61 | 14.07 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.25% |
| Shareholder yield | 0.00% (better) | −0.25% |
| Ownership | ||
| Held by institutions | 53.2% | 108% |
| Held by insiders | – | 1.3% |
| Insider net buying, 12 months | −$988K (better) | −$11.0M |
| Short interest, % of float | – | 10.6% |
Go deeper
- ORGO stock overview
- ORGO income statement
- ORGO valuation and score
- VCEL stock overview
- VCEL income statement
- VCEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.